AR067183A1 - Composiciones terapeuticas y metodos, usos y equipos - Google Patents
Composiciones terapeuticas y metodos, usos y equiposInfo
- Publication number
- AR067183A1 AR067183A1 ARP080102759A ARP080102759A AR067183A1 AR 067183 A1 AR067183 A1 AR 067183A1 AR P080102759 A ARP080102759 A AR P080102759A AR P080102759 A ARP080102759 A AR P080102759A AR 067183 A1 AR067183 A1 AR 067183A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- acceptable
- pharmaceutical use
- inhibits
- ugt
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 150000003839 salts Chemical class 0.000 abstract 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 2
- 230000004060 metabolic process Effects 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 abstract 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 abstract 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 abstract 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229960003277 atazanavir Drugs 0.000 abstract 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 229960002626 clarithromycin Drugs 0.000 abstract 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 1
- 229960003276 erythromycin Drugs 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 229960001936 indinavir Drugs 0.000 abstract 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 abstract 1
- 229960004130 itraconazole Drugs 0.000 abstract 1
- 229960004125 ketoconazole Drugs 0.000 abstract 1
- -1 nefazadone Chemical compound 0.000 abstract 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 abstract 1
- 229960000884 nelfinavir Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 229960001852 saquinavir Drugs 0.000 abstract 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 abstract 1
- 229960003250 telithromycin Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94730607P | 2007-06-29 | 2007-06-29 | |
| US4092008P | 2008-03-31 | 2008-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067183A1 true AR067183A1 (es) | 2009-09-30 |
Family
ID=39831893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102759A AR067183A1 (es) | 2007-06-29 | 2008-06-26 | Composiciones terapeuticas y metodos, usos y equipos |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20100331331A1 (enExample) |
| EP (1) | EP2167088A1 (enExample) |
| JP (3) | JP5547066B2 (enExample) |
| KR (1) | KR20100040892A (enExample) |
| CN (2) | CN101686972B (enExample) |
| AP (1) | AP2965A (enExample) |
| AR (1) | AR067183A1 (enExample) |
| AU (1) | AU2008270630B2 (enExample) |
| BR (1) | BRPI0813000A2 (enExample) |
| CA (1) | CA2692101A1 (enExample) |
| CO (1) | CO6251237A2 (enExample) |
| EA (1) | EA200971093A1 (enExample) |
| EC (1) | ECSP109897A (enExample) |
| IL (1) | IL202744A0 (enExample) |
| MX (1) | MX2009013829A (enExample) |
| NZ (1) | NZ582086A (enExample) |
| SG (1) | SG182229A1 (enExample) |
| TW (1) | TW200914011A (enExample) |
| WO (1) | WO2009006199A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1976517A1 (en) * | 2005-12-30 | 2008-10-08 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| PL2049506T5 (pl) | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| WO2008033836A2 (en) | 2006-09-12 | 2008-03-20 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| MX2009008935A (es) * | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| US20100331331A1 (en) * | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
| AR067184A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| EP2555757B1 (en) * | 2010-04-09 | 2016-05-25 | Bristol-Myers Squibb Holdings Ireland | Atazanavir sulfate formulations with improved ph effect |
| US20130274254A1 (en) * | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| AU2013296289B2 (en) | 2012-08-03 | 2017-10-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| ES2859102T3 (es) | 2013-07-12 | 2021-10-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| WO2015120057A1 (en) * | 2014-02-05 | 2015-08-13 | Gilead Sciences, Inc. | Pharmaceutical combinations against co-infection with hiv and tuberculosis |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| KR20190057158A (ko) | 2015-04-02 | 2019-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6544540B2 (en) * | 1998-07-29 | 2003-04-08 | Syngenta Limited | Base-triggered release microcapsules |
| SK2662004A3 (sk) * | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| EP1758581A1 (en) * | 2004-05-21 | 2007-03-07 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| EP1976517A1 (en) * | 2005-12-30 | 2008-10-08 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| PL2049506T5 (pl) * | 2006-07-07 | 2024-09-09 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości leków |
| WO2008033836A2 (en) * | 2006-09-12 | 2008-03-20 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| US20100331331A1 (en) * | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
| AR067184A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010011963A (es) * | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
-
2008
- 2008-06-26 US US12/666,991 patent/US20100331331A1/en not_active Abandoned
- 2008-06-26 TW TW097123983A patent/TW200914011A/zh unknown
- 2008-06-26 KR KR1020107001981A patent/KR20100040892A/ko not_active Ceased
- 2008-06-26 WO PCT/US2008/068339 patent/WO2009006199A1/en not_active Ceased
- 2008-06-26 CN CN2008800228167A patent/CN101686972B/zh not_active Expired - Fee Related
- 2008-06-26 CN CN201310302662.XA patent/CN103480000A/zh active Pending
- 2008-06-26 EP EP08772024A patent/EP2167088A1/en not_active Withdrawn
- 2008-06-26 CA CA002692101A patent/CA2692101A1/en not_active Abandoned
- 2008-06-26 BR BRPI0813000-0A2A patent/BRPI0813000A2/pt not_active IP Right Cessation
- 2008-06-26 MX MX2009013829A patent/MX2009013829A/es unknown
- 2008-06-26 AU AU2008270630A patent/AU2008270630B2/en not_active Ceased
- 2008-06-26 JP JP2010515112A patent/JP5547066B2/ja not_active Expired - Fee Related
- 2008-06-26 AR ARP080102759A patent/AR067183A1/es not_active Application Discontinuation
- 2008-06-26 SG SG2012046934A patent/SG182229A1/en unknown
- 2008-06-26 AP AP2009005074A patent/AP2965A/xx active
- 2008-06-26 NZ NZ582086A patent/NZ582086A/en not_active IP Right Cessation
- 2008-06-26 US US12/147,041 patent/US20090093467A1/en not_active Abandoned
- 2008-06-26 EA EA200971093A patent/EA200971093A1/ru unknown
-
2009
- 2009-12-15 IL IL202744A patent/IL202744A0/en unknown
- 2009-12-21 CO CO09146055A patent/CO6251237A2/es not_active Application Discontinuation
-
2010
- 2010-01-22 EC EC2010009897A patent/ECSP109897A/es unknown
-
2013
- 2013-07-08 JP JP2013142322A patent/JP5769763B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,798 patent/US20140343063A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094707A patent/JP2015143278A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,084 patent/US20170136001A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008270630B2 (en) | 2014-01-16 |
| ECSP109897A (es) | 2010-03-31 |
| US20100331331A1 (en) | 2010-12-30 |
| BRPI0813000A2 (pt) | 2014-12-23 |
| CN101686972A (zh) | 2010-03-31 |
| JP2010532372A (ja) | 2010-10-07 |
| KR20100040892A (ko) | 2010-04-21 |
| WO2009006199A1 (en) | 2009-01-08 |
| NZ582086A (en) | 2012-07-27 |
| AU2008270630A1 (en) | 2009-01-08 |
| US20170136001A1 (en) | 2017-05-18 |
| AP2965A (en) | 2014-09-30 |
| US20090093467A1 (en) | 2009-04-09 |
| MX2009013829A (es) | 2010-03-10 |
| JP5769763B2 (ja) | 2015-08-26 |
| EP2167088A1 (en) | 2010-03-31 |
| IL202744A0 (en) | 2010-06-30 |
| CO6251237A2 (es) | 2011-02-21 |
| CN103480000A (zh) | 2014-01-01 |
| JP2013199495A (ja) | 2013-10-03 |
| SG182229A1 (en) | 2012-07-30 |
| AP2009005074A0 (en) | 2009-12-31 |
| TW200914011A (en) | 2009-04-01 |
| JP5547066B2 (ja) | 2014-07-09 |
| CN101686972B (zh) | 2013-08-14 |
| US20140343063A1 (en) | 2014-11-20 |
| JP2015143278A (ja) | 2015-08-06 |
| EA200971093A1 (ru) | 2010-08-30 |
| CA2692101A1 (en) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067183A1 (es) | Composiciones terapeuticas y metodos, usos y equipos | |
| SV2010003491A (es) | 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| BR112022003514A2 (pt) | Degradadores bifuncionais de brd9 e seus métodos de uso | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| Gao et al. | Total tanshinones-induced apoptosis and autophagy via reactive oxygen species in lung cancer 95D cells | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| CO2021009083A2 (es) | Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina | |
| AR062401A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis | |
| ECSP034518A (es) | Nuevos retinoides para el tratamiento de enfisema | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| BR112017023076A2 (pt) | derivados do ácido ciclopropanocarboxílico e seus usos farmacêuticos | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| NO20092763L (no) | Isosorbid mononitrat derivater for behandling av tarmlidelser | |
| CO2026000093A2 (es) | Composiciones farmacéuticas para inhibidores de la cinasa nek7 | |
| BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |